KALA BIO

KALA BIO EBITDA per Employee

The EBITDA per Employee of KALA BIO (KALA) as of Nov 18, 2026 is -6.53 M USD. In the previous year, EBITDA per Employee was -6.74 M USD — a change of -3.15% (higher).

EBITDA per Employee

-6.53 MUSD

YoY

-3.15%

Last updated:

EBITDA per Employee of KALA BIO is 2025 -6.53 M USD. EBITDA per Employee of KALA BIO was 2024 -6.74 M USD. It decreases by -3.15% higher compared to the previous year.

The KALA BIO EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-10.85 M USD
Jan 1, 2019
-14.70 M USD
Jan 1, 2020
-16.04 M USD
Jan 1, 2021
-22.37 M USD
Jan 1, 2022
-13.56 M USD
Jan 1, 2023
-6.46 M USD
Jan 1, 2024
-6.74 M USD
Jan 1, 2025
-6.53 M USD
The KALA BIO EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-6.53 MUSD-3.15%
-6.74 MUSD+4.40%
-6.46 MUSD-52.39%
-13.56 MUSD-39.39%
-22.37 MUSD+39.48%
-16.04 MUSD+9.08%
-14.70 MUSD+35.50%
-10.85 MUSD+56.07%
-6.95 MUSD+27.70%
-5.44 MUSD+104.87%
-2.66 MUSD-10.62%
-2.97 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KALA BIO Stock analysis

What does KALA BIO do? Kala Pharmaceuticals, Inc. generates revenue through the development and commercialization of ophthalmic treatments. The company's primary product candidates include KPI-121 1% for post-operative inflammation and pain following ocular surgery, KPI-121 0.25% for temporary relief of dry eye disease symptoms, and the MPP rTKI Program targeting retinal diseases requiring monthly intravitreal injections. Phase III clinical trials have been completed for KPI-121 1%, positioning the company to advance these therapies toward market approval. The firm's focus remains on eye disease treatments with its pipeline products addressing specific clinical needs in ophthalmology. KPI-121 1% is designed for twice-daily administration to treat post-surgical inflammation and pain, while KPI-121 0.25% targets dry eye disease symptoms with a focus on temporary relief. The MPP rTKI Program represents a therapeutic approach for retinal conditions requiring regular intravitreal injections. These product candidates are developed to address unmet medical needs in ophthalmology, with clinical trial data supporting their potential efficacy and safety profiles. The company's revenue model depends on successful clinical outcomes leading to regulatory approvals and subsequent commercial sales. The company's business strategy centers on advancing its ophthalmic pipeline through clinical development stages. KPI-121 1% has completed Phase III trials, indicating a more advanced development stage compared to the other candidates. The MPP rTKI Program is positioned as a treatment for retinal diseases requiring monthly injections, targeting a specific patient segment with chronic conditions. Kala Pharmaceuticals, Inc. aims to secure market access for these therapies through regulatory pathways and commercial partnerships once clinical development is complete. KALA BIO is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KALA BIO stock

EBITDA per Employee of KALA BIO is -6.53 M USD in 2025.

EBITDA per Employee of KALA BIO changed from -6.74 M USD to -6.53 M USD, representing a -3.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee KALA BIO since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's KALA BIO historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — KALA BIO

All Key Metrics — KALA BIO